[FG] Ebrahimi Fahim

In our translational hepatology research group, our research focuses on the origins, adverse outcomes, and treatment strategies in patients with chronic liver diseases, gastrointestinal diseases, and metabolic diseases, with special emphasis on steatotic liver diseases and their complications, including liver cirrhosis and hepatocellular carcinoma. Through population-based large-scale studies, well-characterized prospective cohort studies, and randomized controlled-intervention trials, we aim to identify predictors of disease progression and novel treatment strategies to improve outcomes in these patients. Our work addresses the growing global burden of metabolic dysfunction-associated steatotic liver disease (MASLD), which has emerged as a leading cause of chronic liver disease worldwide. We investigate the complex interplay between metabolic dysfunction, hepatic inflammation, and fibrogenesis that drives disease progression. By integrating clinical, genetic, and metabolic data, our research seeks to advance precision medicine approaches for risk stratification and personalized therapeutic interventions, ultimately aiming to prevent cirrhosis and hepatocellular carcinoma development in high-risk populations.